Eric Jonasch

4.9k total citations · 1 hit paper
74 papers, 2.6k citations indexed

About

Eric Jonasch is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Eric Jonasch has authored 74 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 32 papers in Molecular Biology and 32 papers in Cancer Research. Recurrent topics in Eric Jonasch's work include Renal cell carcinoma treatment (48 papers), Cancer Genomics and Diagnostics (25 papers) and Renal and related cancers (19 papers). Eric Jonasch is often cited by papers focused on Renal cell carcinoma treatment (48 papers), Cancer Genomics and Diagnostics (25 papers) and Renal and related cancers (19 papers). Eric Jonasch collaborates with scholars based in United States, Spain and United Kingdom. Eric Jonasch's co-authors include Frank G. Haluska, Jianjun Gao, W. Kimryn Rathmell, Nizar M. Tannir, Pheroze Tamboli, Christopher G. Wood, Elizabeth R. Plimack, Surena F. Matin, Jay T. Bishoff and Sam S. Chang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Eric Jonasch

66 papers receiving 2.6k citations

Hit Papers

Renal cell carcinoma 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Renal cell carcinoma
    2014 487 citations Eric Jonasch, Jianjun Gao et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Jonasch United States 24 1.4k 1.3k 778 656 380 74 2.6k
Nancy Lewis United States 29 811 0.6× 875 0.7× 1.5k 2.0× 354 0.5× 516 1.4× 62 2.9k
Antonio Silvani Italy 28 765 0.6× 944 0.7× 931 1.2× 398 0.6× 463 1.2× 182 3.3k
Marlena S. Fejzo United States 33 818 0.6× 971 0.7× 544 0.7× 312 0.5× 287 0.8× 68 3.0k
Geon Kook Lee South Korea 30 1.1k 0.8× 866 0.7× 900 1.2× 607 0.9× 249 0.7× 93 2.6k
Taishi Harada Japan 27 1.4k 1.0× 855 0.6× 1.5k 1.9× 316 0.5× 219 0.6× 114 2.6k
Paul B. Romesser United States 25 865 0.6× 654 0.5× 958 1.2× 296 0.5× 342 0.9× 112 2.7k
Isla P. Garraway United States 24 1.2k 0.9× 1.3k 1.0× 903 1.2× 570 0.9× 283 0.7× 70 2.7k
Kathryn A. Gold United States 29 1.8k 1.4× 922 0.7× 2.1k 2.8× 463 0.7× 297 0.8× 99 3.5k
Edurne Arriola Spain 27 931 0.7× 662 0.5× 1.4k 1.8× 604 0.9× 222 0.6× 122 2.3k
Fernando Ferrer United States 28 785 0.6× 1.6k 1.2× 381 0.5× 449 0.7× 224 0.6× 104 3.0k

Countries citing papers authored by Eric Jonasch

Since Specialization
Citations

This map shows the geographic impact of Eric Jonasch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Jonasch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Jonasch more than expected).

Fields of papers citing papers by Eric Jonasch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Jonasch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Jonasch. The network helps show where Eric Jonasch may publish in the future.

Co-authorship network of co-authors of Eric Jonasch

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Jonasch. A scholar is included among the top collaborators of Eric Jonasch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Jonasch. Eric Jonasch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Jonasch, Eric, et al.. (2025). Overlappying the Overlap: Unraveling West Nile Virus Infection in Immune Checkpoint Inhibitor Overlap Syndrome. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A3973–A3973.
3.
Larcher, Alessandro, Riccardo Campi, Axel Bex, et al.. (2025). Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors. European Urology. 88(4). 341–358. 2 indexed citations
4.
Wilson, Neil, Devaki Shilpa Surasi, Tharakeswara Bathala, et al.. (2025). Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.. Journal of Clinical Oncology. 43(5_suppl). 558–558.
5.
Wang, Jianbo, Matthew T. Campbell, Amishi Y. Shah, et al.. (2023). A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.. Journal of Clinical Oncology. 41(6_suppl). TPS745–TPS745. 1 indexed citations
6.
Wang, Lin, Arielle G. Bensimon, Murali Sundaram, et al.. (2023). Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan.. Journal of Clinical Oncology. 41(6_suppl). 733–733. 2 indexed citations
7.
Hasanov, Elshad, Lesley Flynt, Rebecca S. Tidwell, et al.. (2023). STARLITE 1: Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC. The Oncologist. 28(Supplement_1). S13–S13. 3 indexed citations
8.
Maiti, Abhishek, Pavlos Msaouel, Lance C. Pagliaro, et al.. (2017). Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clinical Genitourinary Cancer. 16(1). e47–e57. 18 indexed citations
9.
Kalra, Sarathi, Brian I. Rini, & Eric Jonasch. (2015). Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Annals of Oncology. 26(7). 1300–1304. 33 indexed citations
10.
Wong, Michael K., Eric Jonasch, Sumanta K. Pal, et al.. (2015). Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opinion on Pharmacotherapy. 16(6). 805–819. 5 indexed citations
11.
Lara, Primo N. & Eric Jonasch. (2015). Kidney Cancer. DIAL (Catholic University of Leuven).
12.
Zhao, Qi, Otávia L. Caballero, Ian D. Davis, et al.. (2013). Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas. Clinical Cancer Research. 19(9). 2460–2472. 64 indexed citations
13.
Jonasch, Eric, Pamela K. Allen, Jeffrey S. Weinberg, et al.. (2012). The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma. American Journal of Clinical Oncology. 36(6). 620–624. 42 indexed citations
14.
Tannir, Nizar M., et al.. (2011). Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. Current Clinical Pharmacology. 6(3). 144–150. 14 indexed citations
15.
Jonasch, Eric, et al.. (2011). Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. 117(21). 4958–4965. 38 indexed citations
16.
Kim, Jean Hee, Eric Jonasch, Angela Alexander, et al.. (2008). Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma. Clinical Cancer Research. 15(1). 81–90. 51 indexed citations
17.
Tsao, Chun C., Bin Tean Teh, Eric Jonasch, et al.. (2008). Inhibition of Mxi1 suppresses HIF-2α-dependent renal cancer tumorigenesis. Cancer Biology & Therapy. 7(10). 1619–1627. 15 indexed citations
18.
Margulis, Vitaly, Christopher G. Wood, Eric Jonasch, & Surena F. Matin. (2008). Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Current Oncology Reports. 10(3). 253–258. 5 indexed citations
19.
20.
Janssen, Richard A. J., et al.. (1998). Ras- and Raf-induced Down-modulation of Non-muscle Tropomyosin Are MEK-independent. Journal of Biological Chemistry. 273(48). 32182–32186. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nancy Lewis Breakdown of academic impact, for papers by Antonio Silvani Breakdown of academic impact, for papers by Marlena S. Fejzo Breakdown of academic impact, for papers by Geon Kook Lee Breakdown of academic impact, for papers by Taishi Harada Breakdown of academic impact, for papers by Paul B. Romesser Breakdown of academic impact, for papers by Isla P. Garraway Breakdown of academic impact, for papers by Kathryn A. Gold Breakdown of academic impact, for papers by Edurne Arriola Breakdown of academic impact, for papers by Fernando Ferrer
Rankless by CCL
2026